We’ll be joining Intel in their booth #2661 to share insights on NGS-based genetic testing across a range of cancer, hereditary, and rare diseases and you’re welcome to stop by to learn more. We would also like to invite you to join the HIMSS17 Lunch & Learn: Enabling Precision Medicine Through NGS-based Screening and Diagnostic Testing
Monday, February 20, 2017, 11:15 am – 12:15 pm, Room 202A
Ramon Felciano, CTO and Vice President,
Technology and Global Strategy Global Manager, Clinical Testing Solutions, QIAGEN Bioinformatics
Kristina Kermanshahche, Global Director Life Sciences, Intel
Our topics include NGS-based genetic testing across a range of cancer, hereditary, and rare diseases.
Learn how a leading academic hospital used a robust informatics platform to accelerate the deployment of validated precision medicine capabilities from sample to insight.
We (QIAGEN) provide an instrument-, platform-, assay- and pipeline-agnostic solution, that enables health care providers to scale sequencing, analysis, interpretation and reporting of screening, diagnostic and monitoring test offerings, fully integrated with hospital information systems.
Join the discussion on the importance of cost-effective and automated approaches for scaling an organizational capacity for analysis, classification and clinical reporting of relevant variants for delivery to physician providers.
If this is the first you’ve heard about HIMSS17 – which is the Health IT Conference 2017 – you can find more information on their website http://www.himssconference.org
© QIAGEN 2017. All rights reserved - Trademarks & Disclaimers